Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma
It's a single arm, open label prospective study, in which the safety and efficacy of autologous CAR-T are evaluated in refractory/relapsed B cell lymphoma patients.

Abbreviation: CAR-T: Chimeric Antigen Receptor T-Cell Immunotherapy.
B Cell Lymphoma
COMBINATION_PRODUCT: CAR-T
complete remission rate, complete remission rate after treated by CAR-T therapy, every 3 months until 20 months after the last patient's enrollment
progression free survival, from date of inclusion to date of progression, relapse, or death from any cause, from the day of treatment to the date of first documented progressionï¼Œup to 20 months after the last patient's enrollment|overall survival, from the date of inclusion to date of death, irrespective of cause, 20 months after the last patient's enrollment|adverse events, any unfavorable and unintended sign , symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure, from the date of the start of treatment to 20 months after last patient's enrollment|duration of the modified T cells by CAR-T in the patients, time from re-transfusion to date when the modified T cells become non-detectable., from the date of re-transfusison to 20 months after last patient's enrollment
It's a single arm, open label prospective study, in which the safety and efficacy of autologous CAR-T are evaluated in refractory/relapsed B cell lymphoma patients.

Abbreviation: CAR-T: Chimeric Antigen Receptor T-Cell Immunotherapy.